2 months Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer Zacks
SMMT’s Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab’s development beyond the NSCLC indication.
XSMMT’s Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab’s development beyond the NSCLC indication.
XThe Stock Market News is a financial news aggregator for traders and investors that proposes to you the latest breaking news headlines on global financial markets, economy and business. Live qoute and chart technical analysis, opinion, price forecast on current stock market, currencies (Forex), cryptocurrency, commodities futures, ETFs, funds, bonds and more. Disclaimer: by using any material of this website, you acknowledge and agree that TheStockMarketNews.com is not responsible for the content, actions or any legal issues arising from third-party websites; materials of this website are not financial advice or call to actions. Trading and investing in financial instruments involve high risks including the risk of investment loss.